Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: A comparison based on meta-analyses

Matricardi, Paolo Maria; Kuna, Piotr; Panetta, Valentina; Wahn, Ulrich; Narkus, Annemie

doi:10.1016/j.jaci.2011.03.049

Cited by 94 publications

(35 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following 60 min of CDA provocation, subjects exited the EEC and within 15 min trained staff collected their NLF, NS, and assessed the conjunctival redness. Based on criteria from our previous study and other meta-analyses [26,27], in order to be eligible for treatment randomization and study continuation, subjects had to be deemed CDA responders by having at least a 10% decrease in nasal patency and a positive change from baseline of ≥20% of the TNSS during the EEC CDA challenge. …”

Section: Methodsmentioning

confidence: 99%

A Pilot Study Investigating Clinical Responses and Biological Pathways of Azelastine/Fluticasone in Nonallergic Vasomotor Rhinitis before and after Cold Dry Air Provocation

Singh¹,

Bernstein²,

Lorentz³

et al. 2017

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Nonallergic vasomotor rhinitis (NAVMR) has been considered a diagnosis by exclusion due to unknown mechanisms or lack of diagnostic biomarkers. Methods: To determine clinical responses and biological pathways in NAVMR subjects challenged to cold dry air (CDA) in an environmental exposure chamber (EEC) pre- and posttreatment with azelastine/fluticasone (AzeFlu), 30 NAVMR subjects, prescreened for CDA-induced symptoms (approx. 14°C, <15% relative humidity, ×1 h) were randomized to treatment with AzeFlu (n = 20) or placebo (n = 10) for 2 weeks. Total nasal symptoms scores, minimum cross-sectional area, cough, and conjunctival redness were recorded at visit 1 (pretreatment) and visit 2 (posttreatment) before, during, and after CDA challenge. At both visits, nasal lavage fluid (NLF) and nasal scrapings (NS) were collected pre- and post-CDA challenge. Substance P, neurokinin-A, and calcitonin gene-related peptide concentrations in NLF were analyzed pre- and postchallenge at each visit. Their relationship with CDA-induced symptoms was determined by statistical analysis. MicroRNA sequencing from NS determined differentially expressed miRNA between the treatment groups post-CDA challenge at each visit. Results: The minimum cross-sectional area (p < 0.05), cough count (p < 0.05), and substance P (p < 0.01) improved posttreatment with AzeFlu versus placebo. Gene targets for differentially expressed miRNAs at visit 1 were enriched for biological pathways regulating epithelial ciliogenesis and cell integrity that were modified in the AzeFlu-treated group versus placebo posttreatment. Conclusions: This study demonstrated the feasibility of an EEC model to investigate CDA-induced clinical responses and pathobiology in NAVMR subjects pre- and posttreatment with AzeFlu. NAVMR disease mechanisms for other nonallergic triggers can be investigated similarly.

show abstract

Section: Methodsmentioning

confidence: 99%

A Pilot Study Investigating Clinical Responses and Biological Pathways of Azelastine/Fluticasone in Nonallergic Vasomotor Rhinitis before and after Cold Dry Air Provocation

Singh¹,

Bernstein²,

Lorentz³

et al. 2017

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…Despite differences in the study design of trials analyzing the efficacy of symptomatic treatments and of SIT there is ecidence that the therapeutic effect of SCIT is superior to that of symptomatic medication even during the first year of treatment (Table 2) (22).…”

Section: The Treatment Of Allergic Diseases Of the Respiratory Tractmentioning

confidence: 99%

Specific Immunotherapy

Klimek¹,

Kopp²,

Virchow³

2013

Deutsches Ärzteblatt International

View full text Add to dashboard Cite

show abstract

“…The efficacy of SCIT has been shown to be superior to that of symptomatic drug treatment, even after the first year of treatment [19]. A dose-response curve could be defined for SIT [13].…”

Section: Treatment Of Allergic Diseases Of the Respiratory Tractmentioning

confidence: 99%

A comparison of immunotherapy delivery methods for allergen immunotherapy

Klimek

Pfaar

2013

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

Background: Allergic diseases are among the most common diseases in humans. Besides allergen avoidance, allergen-specific immunotherapy is the only causative treatment option. During recent years, many innovations of this therapy have emerged. Methods: Selective literature research in Medline and PubMed, under the inclusion of national and international guidelines and Cochrane meta analyses. Results: In several meta-analyses, the clinical efficacy of subcutaneous immunotherapy (SCIT) has been largely demonstrated. Recently, major research activities in mucosal immunotherapies focused on the sublingual application route. There are well-documented clinical data on the efficacy and safety of this form of immunotherapy. New application routes as well as new immune-modifying agents such as virus-like particles or CpG-motifs have also been investigated. Conclusion: SIT is accepted to be the only causative treatment option for allergies. New application routes and new immune-modifying agents will allow for different delivery methods in the future.

show abstract

Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: A comparison based on meta-analyses

Cited by 94 publications

References 57 publications

A Pilot Study Investigating Clinical Responses and Biological Pathways of Azelastine/Fluticasone in Nonallergic Vasomotor Rhinitis before and after Cold Dry Air Provocation

A Pilot Study Investigating Clinical Responses and Biological Pathways of Azelastine/Fluticasone in Nonallergic Vasomotor Rhinitis before and after Cold Dry Air Provocation

Specific Immunotherapy

A comparison of immunotherapy delivery methods for allergen immunotherapy

Contact Info

Product

Resources

About